Loading candles…
Piramal Pharma Limited entered the pharmaceutical industry in 1988 through the acquisition of Nicholas Laboratories. The company operates globally, offering end-to-end drug development and manufacturing solutions across several segments including Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG), and consumer healthcare. Its products and services encompass comprehensive drug development and manufacturing solutions. Piramal Pharma serves markets in India, North America, the UK/Europe, and over 100 other countries. The company has expanded through mergers, acquisitions, and organic growth, maintaining 17 development and manufacturing facilities. Notable transactions include the sale of its Domestic formulations business to Abbott in 2010 for $3.7 billion and the sale of its Diagnostic Services to Super Religare Laboratories (SRL). Approximately 70% of its revenue comes from regulated markets.
| Type | Details | Date |
|---|---|---|
| Audited Results - Q4 & FY26 | To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for quarter and financial year ended 31st March, 2026. | 28 Apr 2026 |
| Unaudited Results - Q3-FY25 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Nine Mont… | 28 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 5 Nov 2025 |
| Intimation | Intimation as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 | 28 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 14 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.